DIVISLAB2019-04-012019-06-30in-bse-fin:OneOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares DIVISLAB 2019-04-01 2020-03-31 2019-08-01 INR Lakhs First quarter Single segment Pharmaceuticals 2019-04-01 2019-06-30 Unaudited Consolidated 11628800000.00 303200000.00 11932000000.00 5099200000.00 12300000.00 -588200000.00 1408600000.00 3200000.00 438300000.00 1825500000.00 8198900000.00 3733100000.00 0.00 3733100000.00 956800000.00 51900000.00 1008700000.00 0.00 2724400000.00 0.00 0.00 0.00 0.00 2724400000.00 3000000.00 2727400000.00 0.00 0.00 0.00 0.00 530900000.00 2 10.26 10.26 0.00 0.00 10.26 10.26 1. The above consolidated unaudited financial results, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 10th August, 2019. n2. The consolidated results for the quarter ended 30th June, 2019 were subjected to ‘limited review’ by the auditors and their report contains no qualification. n3. The consolidated unaudited results include the financial results of Divi’s Laboratories Limited and its two subsidiaries Divis Laboratories (USA) Inc. and Divi’s Laboratories Europe AG. n4. The group is engaged in the manufacture of Active Pharmaceutical Ingredients, intermediates and nutraceutical ingredients; and the same constitutes as a single reportable business segment as per Ind AS 108. n5. These financial results have been prepared in accordance with Indian Accounting Standards (‘Ind AS’) prescribed under section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015. n6. The Ministry of Corporate Affairs (MCA), on 30th March, 2019, notified lnd AS 116 Leases as part of the Companies (India Accounting Standard) Amendment Rules, 2019. The new standard is effective for accounting periods beginning on or after 1st April, 2019. The adoption of the standard did not have any material impact to the financial results of the Company. n7. Details of forex gain/loss are given below: n ( . in lakhs) n t Quarter endedt Year Ended n 30.06.2019 (Unaudited)31.03.2019(Unaudited)*30.06.2018(Unaudited)*31.03.2019(Audited) nForex gain/ (loss)t (612)t (611)t 2631t 3086 nForex gain has been included in Other Income and loss has been included in Other Expenses. n8. *The figures for the quarter ended 31st March, 2019 and the quarter 30th June, 2018, included in the statement of consolidated unaudited financial results for the quarter ended 30th June, 2019 have been approved by the Holding company’s Board of directors, but have not been subjected to review as the mandatory requirement for limited review has been made applicable for periods beginning 01st April 2019, pursuant to regulation 33(8) of SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015, as amended. n9. ** Amount is below the rounding off norm adopted by the group. n10. Figures for the previous year/period have been reclassified/ regrouped wherever necessary to conform to current period’s classification. n Other Expenses 1825500000.00